May 27, 2021. FDA scientists note substantial problems with the study sample. These study shortcomings are even more worrisome since the sample was very small.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Written Statement for North Salem Central School District Board of Education
May 12, 2021: Dr. Diana Zuckerman, president of NCHR, writes to the North Salem Central School District Board of Education on the dangers of artificial turf.
Read More »NCHR Written Statement for North Salem Central School District Board of Education
May 12, 2021: Dr. Diana Zuckerman, president of NCHR, writes to the North Salem Central School District Board of Education on the dangers of artificial turf.
Read More »NCHR’s Testimony at FDA Advisory Committee Meeting on Avacopan
May 6, 2021: Although AAV is a serious disease with an unmet need for new treatments, avacopan has not clearly demonstrated that it is more effective than the existing treatments, and it apparently carries more risk for certain adverse events.
Read More »NCHR Statement at FDA Advisory Committee Meeting on Keytruda and Tecentriq for Advanced Urothelial Carcinoma
April 28, 2021: Patients have suffered from taking cancer drugs that aren’t proven to work. Other treatment options are proven to work. Physicians can still choose whatever treatments are on the market, but treatment decisions shouldn’t be based on the mistaken belief that these drugs are proven effective for advanced urothelial carcinoma.
Read More »